Multiple Myeloma: E1A11 (Hematology Oncology Associates)

ECOG-ACRIN E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)


This study has two parts, the first part is related to the initial treatment of patients with multiple myeloma (also called induction) and a second part is related to continued long term control of the myeloma (also called maintenance).

The purpose of the first part of the study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone, on patients with multiple myeloma to find out which is better. In this study, patients will get either the combination that contains carfilzomib or that containing bortezomib. They will not get both.

Following the initial treatment of multiple myeloma (induction), the second part of the study will examine if it is better to continue lenalidomide until the myeloma comes back or limit it for a defined period of 2 years.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Multiple Myeloma
Eastern Cooperative Oncology Group
Katy D'Aprile, RN, BSN at 563-355-7733


  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office